Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on July 29, 2014, to report its financial results for the quarter ended June 30, 2014. The primary purpose of this filing is to provide investors with timely information regarding the company's performance. The press release containing these results is attached as Exhibit 99.1, which is incorporated by reference into this report.
Key Highlights
- 1Vertex Pharmaceuticals announced its financial results for the second quarter of 2014.
- 2The company filed a Form 8-K to officially report these results.
- 3The detailed financial performance for the quarter ended June 30, 2014, is available in the attached press release (Exhibit 99.1).
- 4This filing serves as official notification of the company's operational and financial status for the period.
- 5Investors can refer to Exhibit 99.1 for specific figures related to revenue, expenses, and profitability.
- 6The information is furnished under Item 2.02 of Form 8-K, relating to Results of Operations and Financial Condition.
Frequently Asked Questions
The detailed financial results for the quarter ended June 30, 2014, are provided in the press release attached as Exhibit 99.1 to this Form 8-K filing.
This 8-K filing is significant because it officially reports Vertex Pharmaceuticals' consolidated financial results for the second quarter of 2014, providing investors with crucial performance data in a timely manner.
The information furnished in Exhibit 99.1 (the press release) is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section, unless specifically incorporated by reference into another filing.